TrialJAMA2005

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

John H Alexander et al.PubMed ↗Publisher ↗

No numbers read from the abstract.